Modality
mRNA
MOA
VEGFi
Target
BCMA
Pathway
Amyloid
Alzheimer'sIgAN
Development Pipeline
Preclinical
~Dec 2022
→ ~Mar 2024
Phase 1
Jun 2024
→ Apr 2028
Phase 1Current
NCT07409942
422 pts·IgAN
2024-06→2028-04·Terminated
422 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-272.1y awayInterim· IgAN
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Termina…
Catalysts
Interim
2028-04-27 · 2.1y away
IgAN
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07409942 | Phase 1 | IgAN | Terminated | 422 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA |